These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11845016)

  • 1. Cost of illness studies in rheumatic diseases.
    Fautrel B; Guillemin F
    Curr Opin Rheumatol; 2002 Mar; 14(2):121-6. PubMed ID: 11845016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of rheumatic disorders in the Netherlands.
    van den Akker-van Marle ME; Chorus AM; Vliet Vlieland TP; van den Hout WB
    Best Pract Res Clin Rheumatol; 2012 Oct; 26(5):721-31. PubMed ID: 23218434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: a review of the literature, 2001-2002.
    Tella MN; Feinglass J; Chang RW
    Curr Opin Rheumatol; 2003 Mar; 15(2):127-31. PubMed ID: 12598799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodologic standards.
    Solomon DH; Bates DW; Panush RS; Katz JN
    Ann Intern Med; 1997 Jul; 127(1):52-60. PubMed ID: 9214253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capturing all of the costs in NICE appraisals: the impact of inflammatory rheumatic diseases on productivity.
    Bojke L; Spackman E; Hinde S; Helliwell P
    Rheumatology (Oxford); 2012 Feb; 51(2):210-5. PubMed ID: 22267153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology.
    Gabriel SE; Tugwell P; Drummond M
    Ann Rheum Dis; 2002 Apr; 61(4):370-3. PubMed ID: 11874847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update: direct and indirect costs of arthritis and other rheumatic conditions--United States, 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2004 May; 53(18):388-9. PubMed ID: 15138399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.
    Huscher D; Merkesdal S; Thiele K; Zeidler H; Schneider M; Zink A;
    Ann Rheum Dis; 2006 Sep; 65(9):1175-83. PubMed ID: 16540552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic issues with new rheumatologic therapeutics.
    Kavanaugh A
    Curr Opin Rheumatol; 2007 May; 19(3):272-6. PubMed ID: 17414954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Socio-economic inequalities in occurrence and health care costs in rheumatic and musculoskeletal diseases: results from a Spanish population-based study including 1.9 million persons.
    Putrik P; Ramiro S; Orueta JF; Keszei A; Alonso Moran E; Nuño Solinis R; Boonen A
    Clin Exp Rheumatol; 2018; 36(4):589-594. PubMed ID: 29465359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A summary of economic evaluations published in the field of rheumatology and related disciplines.
    Ferraz MB; Maetzel A; Bombardier C
    Arthritis Rheum; 1997 Sep; 40(9):1587-93. PubMed ID: 9324012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis.
    Boonen A; van den Heuvel R; van Tubergen A; Goossens M; Severens JL; van der Heijde D; van der Linden S
    Ann Rheum Dis; 2005 Mar; 64(3):396-402. PubMed ID: 15271773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone and joint diseases around the world. Sweden: a brief update on burden and priority.
    Akesson K
    J Rheumatol Suppl; 2003 Aug; 67():38-40. PubMed ID: 12926652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life effectiveness of spa therapy in rheumatic and musculoskeletal diseases: a retrospective study of 819 patients.
    Karagülle M; Kardeş S; Karagülle MZ
    Int J Biometeorol; 2017 Nov; 61(11):1945-1956. PubMed ID: 28560466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis.
    Her M; Kavanaugh A
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S107-11. PubMed ID: 23078839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What are the costs of childhood-onset rheumatic disease?
    Minden K
    Best Pract Res Clin Rheumatol; 2006 Apr; 20(2):223-40. PubMed ID: 16546054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic impact of the rheumatic diseases in the United States.
    Felts W; Yelin E
    J Rheumatol; 1989 Jul; 16(7):867-84. PubMed ID: 2527991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct and indirect costs of arthritis and other rheumatic conditions--United States, 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2003 Nov; 52(46):1124-7. PubMed ID: 14627951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic impact of rheumatologic disorders.
    Sangha O; Stucki G
    Curr Opin Rheumatol; 1997 Mar; 9(2):102-5. PubMed ID: 9135912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis.
    Merkesdal S; Ruof J; Huelsemann JL; Schoeffski O; Maetzel A; Mau W; Zeidler H
    J Rheumatol; 2001 Mar; 28(3):657-61. PubMed ID: 11296977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.